BMS posts RELATIVITY-106 liver cancer results; files two new Phase 1/2 trials

Bristol-Myers Squibb's week includes its first posted trial results alongside two newly registered early-phase studies.

• "RELATIVITY-106" (NCT05337137), a Phase 1/2 trial testing nivolumab plus relatlimab and bevacizumab against nivolumab and bevacizumab alone in untreated advanced or metastatic hepatocellular carcinoma, is now listed as completed with results first posted. The study was designed to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma.¹ It enrolled 82 participants.¹ The trial's primary completion was actual as of July 5, 2025, with study completion on November 18, 2025.¹
• Bristol-Myers Squibb registered a Phase 1 trial of BMS-986553 (NCT07873931), described as CD19 in vivo CAR T cells, in refractory autoimmune diseases. The study aims to evaluate safety and tolerability in participants with refractory autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myopathies, systemic sclerosis, rheumatoid arthritis, and Sjögren's disease.² Planned enrollment is 60 participants.² The trial is not yet recruiting, with an estimated start of October 30, 2026.
• "ROSETTA Lung-220" (NCT07871214), the previously reported Phase 2 platform trial of pumitamig-based neoadjuvant regimens in resectable Stage IIA to IIIB non-small cell lung cancer sponsored by Bristol-Myers Squibb with BioNTech SE as collaborator, remains not yet recruiting. The study aims to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer.³ Planned enrollment is 80 participants, with estimated primary completion on March 15, 2028.³